float like butterfli bring sting
pleas refer disclosur appendix analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
contact svb leerink editori depart descript benchmark avail contact svb leerink
approach mont carlo simul entir immuno-
risk dynam consid
probabl technic
probabl disrupt outcom
correl outcom everi
treatment mechanist class
develop path poc trial
probabl mont carlo simul
probabl technic
note use discount rate compani given simul revenu stream alreadi consid mani risk typic account higher discount rate
iob framework object evalu breakthrough
potenti io pipelin mechan asset
score mechan part
iob object assess
biolog clinic evid
mechan asset
coverag import io
biolog evid io space
increasingli import earli stage
signal combin often
sourc svb leerink io team judgement base review literatur compani present svb leerink proprietari survey medacorp immunologist immuno-oncologist februari
overview
valuat risk
aduro invest thesi valuat risk
initi coverag outperform rate pt basi valu clinical-
stage sting agonist program partner nv
sting rank top mechan medacorp io kol panel complementari
checkpoint inhibit posit impact four step adapt immun cycl well nk cell
remain enthusiast despit orr single-ag sting result
line expect murin data checkpoint combin necessari read-through
type interferon agonist checkpoint give us confid combo potenti
though earli broad neutral april antibodi anti-bcma anti-taci potenti
multipl myeloma immunolog view
final though earli excit potenti valu sting inhibit auto-immun
diseas pursu collabor
project revenu deriv mont carlo simul rang outcom
part entir io industri pipelin
valuat price target base dcf analysi simul revenu
cga collabor take account net cash hand overhead cost
sting scope restrict intratumor deliveri and/or limit abscop effect
sting therapeut window prove narrow effect optim patient
failur sting random trial reduc enthusiasm entir sting class despit wide
variat sting molecul select potenc differenti biolog sting versu
competit ever-expand class sting molecul new deliveri platform gsk
sbph codiak other well relat class agonist oncolyt virus
two clinical-stag program b-select platform develop novel immunotherapi
found
us ipo
list
sting agonist modest single-ag
activ studi combin
trial spartalizumab ipilimumab
anti-april mab dual
antagonist activ bcma taci
lilli preclin partnership develop
cgas-st inhibitor auto-immun
sting b-select
timelin key near-term catalyst
escal r/r melanoma feb
initi igan studi healthi
 earlier line scchn
compani report announc strateg focus sting april de-priorit pladd anti-sirp program
valu sting april cga collabor
ionian immuno-oncolog industri analyt note yet give valu iga nephropathi igan program
aduro price target upsid downsid scenario
program
use
one year floor
abscop effect sting
combin limit
tumor alreadi respons
sale
spartalizumab tumor
respons cpi
upsid scenario
see peak annual sale
note yet give valu preclin program clinic program without human data assum overhead result return equal discount rate
recent price reflect mediocr sting data
strateg reset
present data mrk-
single-ag
activ orr
pembro
focus sting
svb leerinksvb cashev tickerratingptdatecloselowhighcap cash-per-share equiv dcfenpvtermin growth rateenpv cga method revenu multiplespeak revenuepeak yeardiscount ratediscount peak revenuerevenu cga platform- sotpenpvenpv/shareenpvenpv/sharenet cga total w/ add method dcfmethod revenu multipl overview key debat center sting
thread
dose needl sting
sting tlr
agonist collaps
therapi
though bell-shap therapeut
window larg mice
sting activ depend immun
cell tumor cell enabl flat
option dose schedul distinct
easili test
imposs predict multipl
complic dose play
like requir extens
dose risk t-cell ablat t-cell
exhaust tumor progress
immun infiltr vari lesion
lesion requir complex dose
type inf primari mechan
activ outsid type inf
result differenti clinic outcom
sting tlr ultim
result indistinguish
intervent radiologist ir
medic oncologist prefer
effect inject mani tumor
support profit reimburs
procedur ir integr
io team commun academia
combin cpi result
benefit cpi unrespons tumor
consist murin data expect
effect combin cpi
therapi simpl deliveri nich
intratumor therapi indic
easili inject lesion
combin cpi give
abscop activ tumor
alreadi respons cpi narrow
scope competit set
effect io combin
therapi singl agent
activ ad synergist activ
cpi still conceptu
summari potenti
discoveri platform novel io therapeut cgas-st b-select
famili proprietari small molecul
potent natur sting
product discov platform
sting pathway antagonist
autoimmun diseas develop
collabor eli lilli
pan method coupl rigor
technolog probe entir b-cell
immun respons yield high-affin
anti-april anti-
licens discov
platform
lead applic tune innat immun cell activ cancer
autoimmun diseas lead sting agonist import valu
adapt compani report
move
combo spartalizumab
combo ipilimumab
combo approv
nv move combin trial
give synergist abscop effect murin model
announc aggress clinic develop strategi sever cancer indic
single-ag studi melanoma amend includ evalu combin
ipilimumab first patient dose feb
initi spartalizumab multipl cancer type expect
initi early-lin head neck cancer expect
base case valuat assum abscop effect combin limit tumor alreadi respons cpi
combo spartalizumab move forward scchn melanoma rcc esophag fl adu-
combo ipilimumab move forward melanoma scchn esophag fl endometri upsid
case assum synergist abscop effect spartalizumab tumor respons cpi includ breast
cancer pancreat ovarian
sting agonist score well biolog dimens iob framework
could improv matur
alpha
score mechan part
includ survey
iob object assess
biolog clinic evid
mechan asset
coverag import io
expect asset move toward
right get clinic evid
combin
sourc svb leerink io team judgement base review literatur compani present svb leerink proprietari survey medacorp immunologist immuno-oncologist februari
merck sting agonist evalu due limit pre-clin data
excit sting agonist class sever risk persist
excit
fulli complementari checkpoint inhibit
cpi prime adapt
innat immun system cold tumor
intratumor deliveri narrow scope cancer
type inject lesion practic
also induc apoptosi sting-high tumor
pre-clin bodi evid substanti
known challeng monitor address
posit read-through multipl trial
type ifn agonist checkpoint
sting rank top mechan
kol chose sting top io
mechan combin
collect panel would alloc
io-portfolio budget sting trial
rang individu kol
kol rank low potenti
lack abscop effect limit benefit local
diseas limit abscop effect limit benefit
checkpoint-respons diseas
dose difficult optim given acut bell-
shape dose curv intratumor deliveri
risk chronic exposur support tumor
invas metastasi
competit type ifn agonist
 idra
emerg greater single-ag and/or
uniqu mechanist combin
activ
svb leerink ionian immuno-oncolog industri analyt model comparison pick medacorp kol top io mechan receiv
alloc theoret io portfolio budget
cgas-st induc antigen present chemokin releas
result t- nk-cell activ tumor clearanc
cgas-st sens pathogen cell stress double-strand dna cyclic
follow ligand bind sting product type interferon ifn chemokin
stimul innat adapt immun
matur tumor-resid dendrit cell present cancer antigen prime cell
t-cell differenti effector teff effector memori tmem t-cell increas product
cytotox protein granzym traffic tumor
sting activ tumor increas express stress ligand render tumor
suscept nk-cell mediat lysi see report nk-cell direct therapi link
tumor microenviron tme chang support t-cell tumor kill
adapt weiss jw et al oncoimm
use sting agonist requir manag t-cell exhaust dose
level shift sting toward direct stimul t-cell apoptosi
increas level ifn stimul also result express tumor cell t-cell
exhaust combin checkpoint inhibitor mitig exhaust mice
intensifi sting respons lead apoptot cell death tumor immun cell
tumor cell still express sting apoptosi could product releas antigen
howev t-cell especi sensit sting abl dose result wide-
spread t-cell death limit durabl immun respons
chronic product inflammatori cytokin could support tumor invas metastas
adapt weiss jw et al oncoimm commun sep cell rep dec li et al sivick ke et al
sever compani develop sting agonist enhanc pathway
activ overcom challeng intratumor deliveri
logic modal
compani asset
ligand activ
human receptor allel
membran penetr pass
cell cell gap-junct
compani report structur ramanjulu jm et al natur synlog poster co-develop ifm therapeut
lead highli competit sting field clinic
efficaci
sting
launch
potenti random data releas potenti trial initi numer preclin asset develop potenti biomark updat dor singl agent
numer pathway stimul type yet clear pathway
differenti factor import clinic treat cancer
mice spontan cell prime anti-tumor surveil depend
sting tlr sting shown potent anti-tumor activ model
sting express across immun tumor cell type may contribut anti-
tumor effect though evid monocyt produc type ifn tumor
cell sting express dispens
type ifn independ sting-inflammasom activ may also contribut immun
surveil set other could contribut tumor progress
similar sting agon result type interferon chemokin respons
express plasmacytoid dc pdc pdc primari role
produc type ifn evid pdc contribut immuno-suppress
tme tlr activ overcom
cpg-a agonist strong induc type ifn alon cpg-c
agonist induc type ifn well inflammatori cytokin chemokin could
recruit t-cell could also contribut tumor progress
clinic valid t-vec approv cavatak evid abscop effect
human pathogen stimul may natur avoid abl dose risk immun system
respond viral-specif t-cell effect kill tumor
clinic valid chemo radiat approv prime immun system
tumor cell death type ifn damag nucleic acid engag
mani immunologist still believ immuno-abl impact chemo result
agent replac target immuno-stimul io combo
medacorp io kol panel survey medacorp kol panel svb leerink woo et al li et al sivick ke et al viralyt investor
present jan emen middleton sharabi et al gaidt et al kantono et al swiecki et al ruffel
within innat immun activ modal compani
util differenti technolog deliv therapeut benefit
mk-
cpg-c odn
compani report list exemplari extens list therapi develop
data readout import catalyst
sting agonist potenti
 initi exost codiak bioscienc
initi dose escal r/r melanoma
initi earlier line
ind submiss
ind submiss
first half rel quiet sting agonist initi single-ag
combin studi late highlight data present
potenti could provid insight clinic dose sting therapi
competit landscap
though sting promis biolog potenti promis clinic signal
base mostli read-through sever challeng remain
attribut like requir clinic success
anti-tumor activ anim model
moa alter immun cell function activ
structure-funct relationship sting agonist
pharmacokinet pharmacodynam dose
determin therapeut window sting
activ clinic
identif respond patient popul
show synergist effect clinic
combin cancer immunotherapi
checkpoint cytokin vaccin nk-base
combin checkpoint
sting agonist
potent murin model
activ orr
remain thread dose
abscop effect signal os
intratumor deliveri
sting
combin
small numer trial
sting agonist impress murin efficaci though establish
durabl immun requir combin checkpoint
impact singl inject mice
implant df tumor
tumor re-challeng mice cure primari tumor
sting agonist alon result tumor clearanc depend cytotox t-cell top left
ad checkpoint inhibit enhanc sting agonist activ inject tumor
requir build durabl immun respons evinc larg improv tumor re-
challeng model top right abscop activ non-inject tumor top middl antigen-
specif t-cell produc sting agon need local tme alter effect
note interpret anti-tumor activ complic simplic anim model abscop
clearanc tumor seen sting high dose like artifact caus diffus
sting agonist inject distal lesion cm small mous
agonist similar sting signal type
interferon sting agonist potent murin model
agonist murin tumor model
sting agonist murin top bottom tumor model
agonist murin tumor model
innat immun cell activ tlr- sting agonist bind differ receptor
respect signal pathway converg increas product type interferon
compar data murin tumor model
sting effect single-ag inject tumor need checkpoint combin
abscop efficaci distant tumor
single-ag tlr agonist minim activ requir combin clear tumor
note sourc may requir subscript
especi encourag antigen specif increas
cytotox t-cell follow sting activ murin experi
sting agonist mice
increas percentag antigen
specif good
antigen specif cell increas
proport cytotox activ
experi rare
biotech/pharma io field
level immun activ difficult
though small patient number multipl clinic trial sting
checkpoint promis result build evid type interferon approach
poor
promis result higher
pembro melanoma
orr
pembro
pembro anti-
tilsotolimod ipilimumab r/r
escal across tumor type orr
present -sitc dynavax present esmo scchn esmo melanoma
idera corpor present antoni riba novel strategi
augment efficaci immunotherapi harrington et al poster present esmo meric-bernstam et al poster present
single-ag show respons hnscc merkel cell
carcinoma well stabl diseas mani tumor type
mice data expect sting
agonist potent
durabl efficaci combin
despit expect across
patient dose escal single-ag
signal efficaci
pr orr merkel cell
carcinoma scchn
three on-going sd rcc
biopsi inject lesion follow three
cycl demonstr increas level
increas stroma stain
lack monotherapi abscop effect
consist pre-clin find
note dmxaa chemo fail show improv chemo alon clinic trial nv later demonstr dmxaa activ human sting
meric-bernstam et al poster present conlon et al jour immun
combin sting agonist checkpoint inhibitor
earli sign clinic benefit sever cancer type
combin pembrolizumab orr partial respons scchn tnbc
anaplast thyroid cancer atc patient
small patient popul data need matur
respons rate similar innat immun cell activ pathway orr scchn
agonist pembrolizumab ppt greater scchn
abscop activ rare observ clinic like requir
broad approv local direct therapi metastat set
meaning clinic outcom like requir local impact
propag distal metastas abscop effect
traffick prime t-cell
hurdl may includ immunosuppress tme lack
chemokin signal distal metastas well poor
human abscop effect rare observ
lead treatment effect local miss os
mice sting tlr oncolyt virus show synergist
abscop effect combin checkpoint and/or co-
human promis data cavatak oncolyt
viru ipilimumab abscop tumor respons
observ clear whether abscop activ
greater would observ ipilimumab alon
look next
lower bar tumor respons checkpoint os
improv intratumor therapi checkpoint
checkpoint action smaller viscer met may
higher bar tumor unrespons checkpoint
synergist benefit intratumor therapi
cavatak treatment r/r melanoma
measur non-inject viscer lesion
note sourc may requir subscript
think may difficult optim human dose sting given bell-
shape dose curv seen mice
magnitud sting respons type interferon
signal lead differ outcom
dose lead t-cell
prime activ subsequ tumor clearanc
abl dose induc apoptosi tumor
cell well immun cell local tumor drain
lymph node tumor shrink short-term
durabl immun
translat middl dose human may
challeng sting agonist innat immun
identifi human immunogen dose
limit apoptot activ immun cell
standard dose patient variabl tumor
may also need optim treatment schedul limit
high dose also result abscop immunogen activ like artifact caus diffus sting agonist one flank small mous
new deliveri platform could address major sting challeng bell-shap
dose abscop effect commerci limit intratumor deliveri
exosom load cdn
rational
platform
system deliveri sting
mani tumor
agonist select dendrit
cell macrophag
innat adapt without
risk exhaust
amen multipl local
resid lung dendrit cell
activ t-cell
antibodi carrier allow
bio-revers linker
releas sting tme
lead t-cell activ
rate howev lower
result
asset
sourc compani report codiak poster keyston dynavax poster spring bank day curadev poster list exemplari
extens list approach develop
first-in-class human antibodi target april
multipl myeloma mm iga nephropathi igan
prolifer induc ligand april
solubl factor bind
bcma highli express
mm signal result increas
prolifer surviv earli clinic
valid bcma-target
car-t
taci express regulatori
t-cell treg gener
bind april block
interact bcma taci
result mm cell death
encourag pre-clin data high ada nhp
potenti risk infect could limit
pre-clin data
block april bind bcma result
treatment anti-april antibodi
deplet april lead select
reduct treg increas immun activ
risk could limit clinic util
dose mg/kg result ada format
nhp
potenti risk infect due reduct
circul igm level shown
clinic develop strategi provid clear
signal anti-april clinic util
announc clinic develop strategi mm igan
result mm dose escal expect
initi igan studi healthi volunt expect
believ design mm provid clear clinic signal go no-go decis
igan clinic indic also support pre-clin nhp data await initi clinic data assign
valu indic model
except per share non-trial intang oper basic share dilut dilut statement
flow base incom oper cash work balanc incl market securitiesbegin balanc sheet
balanc cash expens secur equip lt liabil stockhold current revenu defer stockhold paid appendix
leadership extens drug develop biotech experi
chief execut offic presid
legal offic secretari
on-going combin program sting agonist
sourc compani report potenti random data releas registr trial decis complet enrol
sting express murin tumor dispens
mediat tumor clearanc modul tme
tumor express sting receptor
sensit activ -rigger apoptosi
requir abl dose trigger form
act independ tumor sting
express increas antigen specif t-cell
modul tme reduct tumor
sting agonist effect multipl human allel
form receptor
dmxaa taken clinic base sting agonist activ mice howev later
studi demonstr dmxaa bind human sting receptor
sever sting allel identifi perturb ligand bind pathway activ
aduro spring bank demonstr bind murin
sting receptor well sever allel variant human sting receptor
unclear sting agonist pan-st receptor
corral et al cell report conlon et al jour immun
acronymdefinitionacronymdefinitionacronymdefinitionaaanaplast astrocytomahla-ehuman leukocyt antigen-eoomord magnitudeactadopt t-cell therapyhscthematopoiet stem cell transplantationorrobject respons rateactadopt cell therapyicuintens unitspbnkperipher blood natur killer cellada anti-drug antibodyifninterferonpcrpatholog complet responseadccantibody-depend cellular cytotoxicityiganiga nephropathypdprogress diseaseaicdactiv induc cell lymphoblast leukemiaimidsimmunomodulatori cell death protein myeloid leukemia indinvestig new drugpegpolyethylen glycolankactiv natur killer cellindsinvestig new drug submissionpfsprogression-fre survivalapcsantigen-pres cellsinkipsc-deriv natur killer cellpkpharmacokineticsbcmab-cel matur antigenioimmuno-oncolog pocproof conceptblabiolog licens applicationiobeimmuno-oncolog breakthrough evaluationprparti responseccyrcomplet cytogen responseionianimmuno-oncolog industri analysticsptrsprob technic regulatori successcdnscycl dinucleotid ipintraperitonealrccren cell carcinomaceacarcinoembryon antigenipscinduc pluripot stem cellrgbmrecurr glioblastomacgascycl gmp-amp synthaseiraesimmun relat advers eventsrhggrecurr high grade gliomacmvcytomegalovirusjcdpjoint clinic develop planrr r/rrelaps refractorycpischeckpoint inhibitorskirkil cell immunoglobulin-lik receptor saeseri advers eventcrcomplet remissionmabmonoclon antibodysccsquam cell carcinomacrcomplet responsembcmetastat breast cancerscchnsquam cell carcinoma head neckcricomplet respons incomplet hematolog recoverymcrcmetastat colorect cancersctstem cell transplantcrpccastration-resist prostat cancermcrpcmetastat castrat resist prostat cancersdst diseasecrscytokin releas syndrom mdsmyelodysplast syndromesgotserum glutamic-oxaloacet transaminasedcrdiseas control ratemdscmyeloid-deriv suppressor cellssitcsocieti immunotherapi cancerdltdose-limit toxicitiesmhcmajor histocompat complexstingstimul interferon genesdordur responsemibcmuscl invas bladder cancertacitransmembran activ caml interactordotday therapymmmultipl myelomatamtumor associ maxim effect concentrationmnsclcmetastat non small cell lung cancertiltumor infiltr lymphocytesfapfibroblast activ proteinmrdminim residu diseasetlrstol like receptorsfcfrag crystalliz regionmss-crcmicro-satellit stabl colorect cancer tmetumor toler dosetnbctriple-neg breast tumor base vaccin drug applicationtraetreat relat advers eventgbmglioblastoma multiformendgbmnewly-diagnos glioblastoma uculc colitisgm-csfgranulocyte-macrophag colony-stimul factornhlnon-hodgkin lymphomaucurotheli carcinomagvhdgraft-versus-host diseasenhpnon-human primatevegfvascular endotheli growth factorhankhigh-affin natur killer cellnknatur killervegf rvascular endotheli growth factor receptorhcchepatocellular carcinomanrnuclear receptorvlsvascular leak syndromehcthematopoiet cell transplantnsclcnon small cell lung cancerwbcwhit blood cellshipschuman induc pluripot stem celloicopioid induc constipationwwworldwidehlahuman leukocyt antigen ii
object interpret result single-arm combin trial oncolog
inspir riba propos
threshold requir posit early-stag signal
set
low activ orr
r/r anti-
set
anti-
ppt orr patient
promis result larger size need verifi
ppt orr less patient
ppt delta orr patient
ppt delta orr less patient
ppt delta orr
ppt delta orr
also depriorit unaccept toxic pazopanib rcc
random os need demonstr combin synergist synergist sequenc may prefer given toxic expens
antoni riba novel strategi augment efficaci immunotherapi note sourc may requir subscript
iob framework object evalu breakthrough
potenti io pipelin mechan asset
score mechan
iob object assess
biolog clinic evid
mechan asset
coverag import io
biolog evid io space
increasingli import earli stage
signal combin often
sting activ cancer immun context depend evid immuno
stimul suppress tumor express apoptosi support moa
pre-clin studi demonstr anti-tumor activ sever mous model evid
show tumor clearanc depend sting receptor activ subsequ
evid absolut increas cell increas multipl activ
ifn granzym prolifer marker
safeti nhp human
bind wild-typ murin human sting well mutant human receptor
limit intratumor inject dose window limit concern regard
safe therapeut window small due associ apoptosi high dose
patient scchn merkel cell carcinoma object respons last longer
six month
orr report
approv path like tradit aduro partnership novarit combin
spartalizumab also checkpoint inhibitor
nr specif registr indic announc
total score calcul base weight averag criteria score biolog rational anim model immun cell biolog structure/funct activ criteria
reduc score improv score pk/pd safeti
total score calcul base weight averag criteria score single-arm evid random evid identifi respond popul criteria
reduc score improv score regul risk clinic hurdl
iob evalu criteria evalu single-ag treatment
clariti role cancer immun abil bia activ
desir pleiotropic/context-depend mechan
evid surviv benefit physiolog relev murin
evid impact absolut immun cell count antigen-
specif activ state prolifer marker vitro kill
potenti immun cell isol anim post dose
specif strength target bind
extend benefit evidenc dot bonu long tail
extent clinic impact standard-of-car bonu long tail
eas identifi respond patient popul base orr
presenc pd marker practic half-lif deliveri
width therapeut window
depend novel un-valid outcom trial design
level unmet medic need given current standard care
criteria asset score
score multipli weight risk score neg impact
given lack random data io score weight non-random data plan shift weight time random data emerg
iob evalu criteria evalu combin treatment
clariti role cancer immun abil bia activ
desir pleiotropic/context-depend mechan
evid surviv benefit physiologically-relev murin
evid impact absolut immun cell count antigen-
specif activ state prolifer marker vitro kill
potenti immun cell isol anim post dose
specif strength target bind
extend benefit evidenc dot bonu long tail
evid dot synergi
extent clinic impact standard-of-car bonu long tail
eas identifi respond patient popul base orr
contribut part
evid synergi base increment orr vs backbon
presenc pd marker practic half-lif deliveri
width therapeut window
depend novel un-valid outcom trial design
level unmet medic need given current standard care
criteria asset score
score multipli weight risk score neg impact
given lack random data io score weight non-random data plan shift weight time random data emerg
